Polaryx Therapeutics names Will Charlton chief medical officer ahead of Phase 2 trialSep 1PeoplePolaryx Therapeutics, Inc.
Polaryx registers Phase 2 basket trial of PLX-200 across four pediatric lysosomal disordersJul 31Trial updategemfibrozilPolaryx Therapeutics, Inc.
Sign inSign in